C0005516||Predictive biomarkers
C0006611||MUC1
C0011306||dendritic-cell
C0042210||vaccine
C0677936||refractory
C0007131||non-small cell lung cancer
C0011306||dendritic cell
C0011306||dendritic cell
C0042210||vaccine
C0006611||immunogenic tumor antigen
C0006611||MUC1
C0278348||cancer immunotherapy
C0005516||predictive biomarkers
C4055223||clinical responses
C1711297||vaccine
C0011306||DCs
C1711297||MUC1-derived peptide
C1736929||subcutaneously administered
C0006611||MUC1-positive
C0007131||non-small cell lung cancer
C0007131||non-small cell lung cancer
C0677936||refractory
C0920425||anticancer therapies
C3274448||tolerability
C1711297||vaccine
C0005516||predictive biomarkers
C4055223||clinical responses
C1711297||vaccines
C0042196||vaccination
C0042196||vaccinations
C0599755||cohort
C0877248||immune-related adverse events
C1142480||skin reactions at the vaccination site
C2349672||fever
C2919552||longer survival times
C0877248||immune-related adverse events
C2919552||Longer survival times
C0023508||peripheral white blood cells
C0200635||lymphocytes
C1711297||MUC1
C1817908||cytotoxic immune responses
C0042196||vaccinations
C1711297||MUC1
C0011306||dendritic cell
C1711297||vaccine
C0301872||immune response
C2919552||prolonged survival
C0677936||refractory
C0007131||non-small cell lung cancer
C0877248||immune-related adverse events
C0200635||peripheral lymphocytes
C0005516||predictive biomarkers
C4055223||clinical response
C0278348||cancer immunotherapy
C0007131||non-small cell lung cancer